Vu Eng 101 Assignment 4% Solution 10% Solution 7%Mixture

1. Gittins DI, Bethell D, Schiffrin DJ, Nichols RJ. A nanometre-scale electronic switch consisting of a metal cluster and redox-addressable groups. Nature. 2000;408(6808):67–69.[PubMed]

2. Darroudi M, Ahmad MB, Abdullah AH, Ibrahim NA. Green synthesis and characterization of gelatin-based and sugar-reduced silver nanoparticles. Int J Nanomedicine. 2011;6:569–574.[PMC free article][PubMed]

3. Wise K, Brasuel M. The current state of engineered nanomaterials in consumer goods and waste streams: the need to develop nanoproperty-quantifiable sensors for monitoring engineered nanomaterials. Nanotechnol Sci Appl. 2011;4:73–86.[PMC free article][PubMed]

4. Mukherjee P, Roy M, Mandal BP, et al. Green synthesis of highly stabilized nanocrystalline silver particles by a non-pathogenic and agriculturally important fungus. Tasperellum Nanotechnology. 2008;19(7):075103–075110.[PubMed]

5. Ai J, Biazar E, Jafarpour M, et al. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine. 2011;6:1117–1127.[PMC free article][PubMed]

6. Sastry M, Ahmad A, Khan MI, Kumar R. Biosynthesis of metal nanoparticles using fungi and actinomycete. Curr Sci. 2003;85(2):162–170.

7. Shankar SS, Rai A, Ankamwar B, Singh A, Ahmad A, Sastry M. Biological synthesis of triangular gold nanoprisms. Nat Mater. 2004;3(7):482–488.[PubMed]

8. Binupriya AR, Sathishkumar M, Yun SI. Myco-crystallization of silver ions to nano-sized particles by live and dead cell filtrates of Aspergillus oryzae var viridis and its bactericidal activity towards Staphylococcus aureus KCCM 12256. Ind Eng Chem Res. 2010;49(2):852–858.

9. Shankar SS, Rai A, Ahmad A, Sastry M. Controlling the optical properties of lemongrass extract synthesized gold nanotriangles and potential application in infrared-absorbing optical coatings. Chem Mater. 2005;17(3):566–572.

10. Shankar SS, Rai A, Ankamwar B, Ahmad A, Sastry M. Rapid synthesis of Au, Ag, and bimetallic Au-core-Ag shell nanoparticles using neem (Azadirachta indica) leaf broth. J Colloid Interface Sci. 2004;275(2):496–502.[PubMed]

11. Shankar SS, Ahmad A, Sastry M. Geranium leaf assisted biosynthesis of silver nanoparticles. Biotechnol Prog. 2003;19(6):1627–1631.[PubMed]

12. Huang J, Li Q, Sun D, et al. Biosynthesis of silver and gold nanoparticles by novel sundried Cinnanonumcamphora leaf. Nanotechnology. 2007;18(10):105104–105114.

13. Elavazhagan T, Arunachalam KD. Memecylon edule leaf extract mediated green synthesis of silver and gold nanoparticles. Int J Nanomedicine. 2011;6:1265–1278.[PMC free article][PubMed]

14. Ankamwar B, Damle C, Ahmad A, Sastry M. Biosynthesis of gold and silver nanoparticles using Emblica officinalis fruit extract, their phase transfer and transmetallation in an organic solution. J Nanosci Nanotechnol. 2005;5(10):1665–1671.[PubMed]

15. Panacek A, Kvitek L, Prucek R, et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J Phys Chem B. 2007;110(33):16248–16253.[PubMed]

16. Neu HC. Crisis of antibiotic resistance. Science. 1992;257(5073):1064–1073.[PubMed]

17. Pitout JDD, Sanders CC, Sanders WE. Antimicrobial resistance with focus on β-lactam resistance in Gram-negative bacilli. Am J Med. 1997;103(1):51–59.[PubMed]

18. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis. 1996;25(4):213–217.[PubMed]

19. Shakibaie MR, Dhakephalkar PK, Kapadnis BP, Chopade BA. Removal of silver from photographic wastewater effluent using Acinetobacter baumannii BL54. Can J Microbiol. 1999;45(12):995–1000.[PubMed]

20. Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA. Incidence and prevalence of nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harboring multiple plasmids. Indian J Med Res. 2008;128(8):178–187.[PubMed]

21. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for gram-negative bacteria. J Colloid Interface Sci. 2004;275(1):177–182.[PubMed]

22. Shi Z, Neoh KG, Kang ET. Surface-grafted viologen for precipitation of silver nanoparticles and their combined bactericidal activities. Langmuir. 2004;20(16):6847–6852.[PubMed]

23. Choi HJ, Han SW, Lee SJ, Kim K. Structure and thermal behavior of a layered silver hydroxyalkanecarboxylate. J Colloid Interface Sci. 2003;264(2):458–466.[PubMed]

24. Sautour M, Mitaine-Offer AC, Lacaille-Dubois MA. The Dioscorea genus: a review of bioactive steroid saponins. J Nat Med. 2007;61(2):91–101.

25. Gao H, Kuroyanagi M, Wu L, Kawahara N, Yasuno T, Nakamura Y. Antitumor-promoting constituents from D. bulbifera L. in JB6 mouse epidermal cells. Biol Pharm Bull. 2002;25(9):1241–1243.[PubMed]

26. Bhandari MR, Kawabata J. Organic acid, phenolic content and antioxidant activity of wild yam (Dioscorea. spp.) tubers of Nepal. Food Chem. 2004;88(2):163–168.

27. Ghosh S, Ahire M, Patil S, et al. Antidiabetic activity of Gnidia glauca and Dioscorea bulbifera: Potent amylase and glucosidase inhibitors. Evid Based Complement Alternat Med. 2011;2012(2012):929051.[PMC free article][PubMed]

28. Ghosh S, Patil S, Ahire M, et al. Synthesis of gold nano-anisotrops using Dioscorea bulbifera tuber extract. J Nanomater. 2011;2011[PMC free article][PubMed]

29. Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI. Antioxidant activities of phenolic, proanthocyanidin, and flavonoid components in extracts of Cassia fistula. J Agric Food Chem. 2002;50(18):5042–5047.[PubMed]

30. Wolfe K, Wu X, Liu RH. Antioxidant activity of apple peels. J Agric Food Chem. 2003;51(3):609–614.[PubMed]

31. Thayumanavan B, Sadasivam S. Physicochemical basis for the preferential uses of certain rice varieties. Qual Plant Foods Hum Nutr. 1984;34(4):253–257.

32. Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal Chem. 1959;31(3):426–428.

33. Slack SC, Mader WJ. Colorimetric assay for diosgenin and related compounds. Anal Chem. 1961;33(4):625–627.

34. Sadasivam S, Manickam A. Biochemical Methods. 3rd ed. New Delhi, India: New Age International; 2008.

35. Saffran M, Denstedt OF. A rapid method for the determination of citric acid. J Biol Chem. 1948;175:849–855.[PubMed]

36. Gao H, Hou B, Kuroyanagi M, Wu L. Constituents from anti-tumor-promoting active part of Dioscorea bulbifera L. in JB6 mouse epidermal cells. Asian J Tradit Med. 2007;2(3):104–109.

37. Egorova EM, Revina AA. Synthesis of metallic nanoparticles in reverse micelles in the presence of quercetin. Colloids Surf A Physicochem Eng Asp. 2000;168(1):87–96.

38. Panigrahi S, Kundu S, Ghosh SK, Nath S, Pal T. General method of synthesis for metal nanoparticles. J Nanopart Res. 2004;6(4):411–414.

39. Behera KK, Sahoo S, Prusti A. Biochemical quantification of diosgenin and ascorbic acid from the tubers of different dioscorea species found in Orissa. Lib Agric Res Cent J Int. 2010;1(2):123–127.

40. Suriyavathana M, Indupriya S. Screening of antioxidant potentials in Dioscorea bulbifera. Int J Pharm Life Sci. 2011;2(4):661–664.

41. Qin Y, Ji X, Jing J, Liu H, Wu H, Yang W. Size control over spherical silver nanoparticles by ascorbic acid reduction. Colloids Surf A Physicochem Eng Asp. 2010;372(1–3):172–176.

42. Lee GP, Bignell LJ, Romeo TC, et al. The citrate-mediated shape evolution of transforming photomorphic silver nanoparticles. Chem Commun. 2010;46(41):7807–7809.[PubMed]

43. Dong X, Ji X, Wu H, Zhao L, Li J, Yang W. Shape control of silver nanoparticles by stepwise citrate reduction. J Phys Chem C. 2009;113(16):6573–6576.

44. Guclu-Ustundag O, Mazza G. Saponins: properties, applications and processing. Crit Rev Food Sci Nutr. 2007;47(3):231–258.[PubMed]

45. Nadagouda MN, Hoag G, Collins J, Varma RS. Green synthesis of Au nanostructures at room temperature using biodegradable plant surfactants. Cryst Growth Des. 2009;9(11):4979–4983.

46. Sharma VK, Yngard RA, Lin Y. Silver nanoparticles: Green synthesis and their antimicrobial activities. Adv Colloid Interface Sci. 2009;145(1–2):83–96.[PubMed]

47. Nabikhan A, Kandasamy K, Raj A, Alikunhi NM. Synthesis of antimicrobial silver nanoparticles by callus and leaf extracts from saltmarsh plant, Sesuvium portulacastrum L. Colloids Surf B Biointerfaces. 2010;79(2):488–493.[PubMed]

48. Song JY, Kim BS. Rapid biological synthesis of silver nanoparticles using plant leaf extracts. Bioprocess Biosyst Eng. 2009;32(1):79–84.[PubMed]

49. Sathishkumar M, Sneha K, Yun YS. Immobilization of silver nanoparticles synthesized using Curcuma longa tuber powder and extract on cotton cloth for bactericidal activity. Bioresour Technol. 2010;101(20):7958–7965.

Summary

Background

Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1–5 years with persistent asthmatic symptoms.

Methods

This exploratory 12-week, randomised, double-blind, placebo-controlled, parallel-group, phase 2/3, regulatory multicentre trial was done at 32 hospitals, clinics, and clinical research units in 11 countries in Asia, Europe, and North America. Children aged 1–5 years with at least a 6-month history of persistent asthmatic symptoms and a need for inhaled corticosteroids were eligible. Patients were randomly allocated using an interactive voice or web-based response system to receive once-daily tiotropium 2·5 μg, tiotropium 5 μg, or placebo as an add-on to inhaled corticosteroids with or without additional controller medication. Patients and investigators were masked to study group assignment. Tiotropium was given via the Respimat inhaler once daily as two puffs of 1·25 μg in the 2·5 μg group, two puffs of 2·5 μg in the 5 μg group, or two puffs of placebo. The primary outcomes were safety, which was assessed by comparing adverse events between the tiotropium and placebo groups, and efficacy, which was measured as the change in weekly mean combined daytime asthma symptom score from baseline to week 12. Statistical analyses of treatment effects were exploratory; although endpoints were defined, they were used for descriptive analyses only. The safety and primary analyses were done in all patients who received at least one dose of their assigned treatment. This study is registered with ClinicalTrials.gov (NCT01634113), and is completed.

Findings

Between July 26, 2012, and Dec 4, 2014, 102 children were randomly assigned to the three treatment groups (36 to receive tiotropium 2·5 μg, 32 to receive tiotropium 5 μg, and 34 to receive placebo). 101 children completed the study and were included in the analyses. The changes in adjusted weekly mean combined daytime asthma symptom scores between baseline and week 12 were not significantly different between any of the groups. The adjusted mean difference between the tiotropium 2·5 μg group and placebo group was −0·080 (95% CI −0·312 to 0·152) and the difference between tiotropium 5 μg and placebo group was −0·048 (−0·292 to 0·195). Adverse events were less frequent with tiotropium treatment than with placebo (20 [56%] of 36 children with tiotropium 2·5 μg, 18 [58%] of 31 with tiotropium 5 μg, and 25 [74%] of 34 with placebo), although no formal statistical comparison between groups was performed. A greater proportion of children reported asthma exacerbations as adverse events in the placebo group (ten [29%] of 34) than in the tiotropium groups (five [14%] of 36 in the 2·5 μg group and two [6%] of 31 in the 5 μg group). Serious adverse events were reported in three patients (all of whom received placebo); no adverse events led to discontinuation of treatment or death.

Interpretation

To our knowledge, our small study is the first to assess the safety and efficacy of tiotropium in children aged 1–5 years with persistent asthmatic symptoms. Tolerability of tiotropium was similar to that of placebo, which is consistent with previous findings in older populations. Although mean daytime asthma symptom scores were not significantly different between groups, tiotropium showed the potential to reduce asthma exacerbation risk compared with placebo. The findings of the study are limited by the small sample size and descriptive statistical analyses. Additional well powered trials are needed to further assess the safety and efficacy of tiotropium in young children.

Funding

Boehringer Ingelheim.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *